Your browser is no longer supported. Please, upgrade your browser.
Kezar Life Sciences, Inc.
Index- P/E- EPS (ttm)-1.00 Insider Own1.70% Shs Outstand52.05M Perf Week7.14%
Market Cap658.80M Forward P/E- EPS next Y-1.27 Insider Trans0.00% Shs Float34.98M Perf Month75.50%
Income-51.40M PEG- EPS next Q-0.29 Inst Own60.70% Short Float5.13% Perf Quarter77.26%
Sales- P/S- EPS this Y48.40% Inst Trans3.25% Short Ratio1.38 Perf Half Y147.98%
Book/sh2.30 P/B6.13 EPS next Y-20.60% ROA-35.70% Target Price20.00 Perf Year115.42%
Cash/sh2.59 P/C5.45 EPS next 5Y- ROE-38.70% 52W Range4.61 - 14.70 Perf YTD170.31%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-4.01% Beta0.31
Dividend %- Quick Ratio15.80 Sales past 5Y- Gross Margin- 52W Low206.07% ATR1.15
Employees47 Current Ratio15.80 Sales Q/Q- Oper. Margin- RSI (14)72.22 Volatility7.97% 10.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.10% Profit Margin- Rel Volume1.74 Prev Close13.86
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.30M Price14.11
Recom1.70 SMA2031.72% SMA5049.25% SMA200105.76% Volume2,263,297 Change1.80%
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
Nov-16-21 12:07PM  
Nov-15-21 04:05PM  
Nov-11-21 07:00AM  
Nov-10-21 09:47AM  
Nov-09-21 04:05PM  
Nov-03-21 08:00AM  
Oct-27-21 08:00AM  
Oct-25-21 10:33AM  
Oct-15-21 02:12PM  
Oct-05-21 04:01PM  
Sep-21-21 02:34PM  
Sep-02-21 07:00AM  
Aug-23-21 07:01AM  
Aug-12-21 04:02PM  
Jul-26-21 04:52AM  
Jul-08-21 07:01AM  
Jun-08-21 07:01AM  
Jun-02-21 07:01AM  
Jun-01-21 04:01PM  
May-27-21 07:00AM  
May-26-21 04:01PM  
May-12-21 04:01PM  
May-10-21 04:01PM  
Apr-19-21 06:45AM  
Apr-10-21 08:30AM  
Feb-25-21 04:01PM  
Feb-16-21 12:53AM  
Feb-10-21 04:01PM  
Jan-07-21 04:02PM  
Dec-18-20 03:13AM  
Dec-15-20 07:52AM  
Dec-14-20 04:01PM  
Nov-12-20 04:05PM  
Nov-05-20 04:01PM  
Oct-23-20 07:26AM  
Oct-19-20 02:25PM  
Oct-15-20 07:00AM  
Sep-18-20 07:30AM  
Sep-17-20 04:01PM  
Sep-10-20 07:00AM  
Aug-11-20 08:59AM  
Aug-05-20 04:01PM  
Aug-03-20 04:01PM  
Jul-29-20 05:17PM  
Jun-23-20 09:16PM  
Jun-16-20 09:36AM  
Jun-12-20 07:01AM  
Jun-09-20 04:15PM  
Jun-08-20 08:48PM  
Jun-03-20 04:02PM  
May-28-20 04:01PM  
May-20-20 04:42PM  
May-11-20 10:35AM  
May-07-20 04:01PM  
May-04-20 04:01PM  
Apr-09-20 06:08PM  
Mar-24-20 11:30AM  
Mar-12-20 04:01PM  
Feb-26-20 04:01PM  
Feb-07-20 08:36AM  
Feb-04-20 05:50PM  
Jan-31-20 08:13AM  
Dec-19-19 07:00AM  
Dec-16-19 07:29AM  
Dec-09-19 04:05PM  
Nov-27-19 04:05PM  
Nov-18-19 11:39AM  
Nov-14-19 09:44AM  
Nov-12-19 07:00AM  
Nov-08-19 04:13PM  
Nov-06-19 04:05PM  
Oct-28-19 04:25PM  
Oct-01-19 04:05PM  
Sep-27-19 02:22PM  
Aug-28-19 04:05PM  
Aug-21-19 01:38PM  
Aug-14-19 03:40PM  
Aug-07-19 04:05PM  
Jul-02-19 09:03PM  
Jun-14-19 08:47AM  
Jun-13-19 04:01PM  
Jun-10-19 04:05PM  
May-29-19 07:38AM  
May-28-19 07:31PM  
May-25-19 10:08AM  
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BERGER FRANKLIN MDirectorSep 22Option Exercise5.608,89649,818810,691Sep 23 04:26 PM
BERGER FRANKLIN MDirectorSep 21Option Exercise6.7717,792120,452801,795Sep 23 04:26 PM
Fowler John FranklinCEODec 31Option Exercise0.9016,00014,400359,204Jan 04 08:45 PM